CYCN
Cyclerion Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$23.52
+0.00%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
Key dataSep 14, 2026
Open$30.85
From 52W high−47.34%
Volume52129.00
Market cap$110.11M
P/E (TTM)—
P/S (TTM)58.0x
Div yield—
Key dataSep 14, 2026
Open
$30.85
From 52W high
−47.34%
Volume
52129.00
Market cap
$110.11M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−16.2x
P/E (TTM)
—
RSI (14)
57.1
MomentumView details →
1D Return
+0.00%
YTD Return
+255.57%
SummaryUpdated Jun 1, 2026
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company emerged as a spinoff focused on developing innovative medicines for serious central nervous system diseases and other conditions through its proprietary soluble guanylate cyclase (sGC) platform technology. Since going public in March 2019, Cyclerion has been advancing multiple drug candidates through various stages of clinical development, with a particular emphasis on neurological disorders that have limited treatment options.
Similar companies
Latest newsMore news →